[Home]   [Full version]  

Advance towards early Alzheimer's diagnosis

Jun 18 ,Medicine & Health


The leader of the team that made the discovery, Professor Christopher Rowe of the Austin Hospital in Melbourne, says early diagnosis and treatment presents medical practitioners with the best opportunity to delay the onset of Alzheimer's.

"While the discovery is at an experimental stage, this work places Australia at the forefront of neuro-imaging in Alzheimer's disease," Professor Rowe says.

A 2004 Access Economics report calculated that if the average age of onset of Alzheimer's was raised by just five months, cumulative savings of A$1.3 billion would be realised by 2020 rising to A$6.6 billion by 2040.

Alzheimer's disease is characterised by very high levels of a molecule called beta-amyloid in the brain. The project has demonstrated that a neuro-imaging scan called PiB PET can be used to identify individuals who will develop Alzheimer's disease up to 18 months earlier than all currently available diagnostics.

PiB PET can show the beta-amyloid in the brain which potentially allows clinicians to distinguish patients with early Alzheimer's disease from others without the disease, even before clear signs of memory loss are present.

The research was undertaken as part of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Flagship Study of Ageing.

The AIBL Flagship Study of Ageing is a collaboration initiated by the CSIRO Preventative Health National Research Flagship. AIBL is a joint activity between the University of Melbourne, Edith Cowan University - Western Australia, Neurosciences Australia, Mental Health Research Institute of Victoria and National Ageing Research Institute, and the Preventative Health Flagship.

The leader of the AIBL study, Professor David Ames, says the study has the potential to markedly reduce the burden this disabling illness places on both individuals and society.

"Early presymptomatic diagnosis is an essential development which will allow us to test new disease modifying therapies with the aim of delaying the onset of Alzheimer's disease in susceptible individuals," Professor Ames says.

The Director of CSIRO's Preventative Health National Research Flagship, Dr Richard Head, says the result highlights the value of a national collaborative team working together on one of Australia's biggest challenges.

Alzheimer's Australia has worked closely with AIBL to attract and co-ordinate the many volunteers who have made this study possible.

"Alzheimer's Australia is pleased to be part of this very exciting research and we look forward to its continuation," Alzheimer's Australia National Executive Director, Glenn Rees, says.

Source: CSIRO Australia

Related stories:

Researchers explore the emerging role of infection in Alzheimer's disease
The realization that pathogens can produce slowly progressive chronic diseases has opened new lines of research into Alzheimer's disease. In a special issue of the Journal of Alzheimer's Disease published May 2008, guest editors Judith Miklossy, from the University of British Columbia, and Ralph N. Martins, from Edith Cowan University and Hollywood Private Hospital, Perth, Western Australia, and a group of experts explore this exciting topic.
Key step in the 'puncture' mechanism of cell death revealed
A team of medical researchers led by Dr Ruth Kluck at Melbourne’s Walter and Eliza Hall Institute (WEHI) has discovered a key step in the mechanism by which cells destroy themselves. In this process, called “apoptosis”, certain proteins cause the cell to self-destruct by puncturing its “power plant.” How the proteins do this has been clarified by the WEHI team. The discovery is an important step towards the identification of targets for drugs designed to regulate cell death.
Mental and physical exercise delays dementia in fatal genetic disease
Scientists at Melbourne’s Howard Florey Institute have discovered that mental and physical stimulation delays the onset of dementia in the fatal genetic disease, Huntington's disease.
Virtual 3D nanorobots could lead to real cancer-fighting technology
From eliminating the side effects of chemotherapy to treating Alzheimer’s disease, the potential medical applications of nanorobots are vast and ambitious. In the past decade, researchers have made many improvements on the different systems required for developing practical nanorobots, such as sensors, energy supply, and data transmission.
Drug improves symptoms of severe Alzheimer's disease
A drug initially used to treat mild to moderate Alzheimer’s disease improved the memory and global function of people with severe Alzheimer’s disease and was safe and effective, according to a study published in the July 31, 2007, issue of Neurology, the medical journal of the American Academy of Neurology.
Signs of Alzheimer's disease may be present decades before diagnosis
Scientists from the University of South Florida and the University of Kentucky report that people who develop Alzheimer's disease may show signs of this illness many decades earlier in life, including compromised educational achievement. Their research appears online this month in the journal Alzheimer's Disease and Associated Disorders.
Biological 'Clock' Influences Damage Done by Oxidative Stress
(PhysOrg.com) -- Swing shift workers and frequent fliers beware – scientists have identified yet another biological issue that relates to the “circadian clock” found in almost every species from insects to humans, and discovered that the time of day also affects the ability to resist oxidative stress.
New study finds healthy children of Alzheimer patients show early brain changes
Medical College of Wisconsin researchers in Milwaukee have reported that children of Alzheimer's patients who are carriers of a genetic risk factor for Alzheimer's disease have neurological changes that are detectable long before clinical symptoms may appear.

News discussion:

Medicine & Health news

[Home]   [Full version]